Motoric Cognitive Risk Syndrome Clinical Trial
Official title:
Motoric Cognitive Risk Syndrome: Refining Treatment Strategies and Testing Feasibility to Personalize Treatment for Older Veterans
This study will begin to evaluate personalized preventative dementia treatments for Veterans at risk for developing dementia. The investigators will target Veterans with Motoric Cognitive Risk syndrome (MCR), which is characterized by slow gait speed and cognitive concerns (e.g., problems with memory or concentrations).
Status | Not yet recruiting |
Enrollment | 54 |
Est. completion date | December 31, 2029 |
Est. primary completion date | May 31, 2029 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: 1. Age 65 2. Receiving VA primary care 3. Community-dwelling 4. Motoric Cognitive Risky Syndrome i. Slow gait speed ii. Subjective cognitive concerns/complaints Exclusion Criteria: 1. Non-English speaking 2. Presence of a terminal disease 3. Major medical problem 4. Myocardial infarction or major surgery in the previous 3 months 5. Use of a walker 6. Dementia diagnostic 7. Mobility disability |
Country | Name | City | State |
---|---|---|---|
United States | VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cognition - Executive Function | Change in executive function will be assessed after 12-week exercise treatment using Delis-Kaplan Executive Function System. | Baseline to end of 12-week treatment | |
Primary | Enrollment/Baseline | Enrollment will be defined as the number of participants who were recruited and consented to the study. | Enrollment | |
Primary | Retention | Retention will be defined as the number of participants who completed the 12-week exercise treatment. | Baseline to end of 12-week treatment | |
Primary | Compliance | Compliance will be defined by the proportion of completed treatment sessions. | Baseline to end of 12-week treatment | |
Primary | Acceptability | Acceptability will be recorded by conducting interviews with participants who completed the 12-week exercise treatment. | End of 12-week treatment | |
Secondary | Gait Speed | Change in gait speed will be assessed after 12-week exercise treatment. | Baseline to end of 12-week treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05046275 -
MCR Syndrome in Quebec : Results From NuAge Study
|
||
Enrolling by invitation |
NCT04115215 -
Pre-FRONTal Brain STability, Key for Action Against Disability in AGing
|
N/A | |
Recruiting |
NCT04492241 -
Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution for the Treatment of Motoric Cognitive Risk Syndrome
|
N/A | |
Recruiting |
NCT05640141 -
Pre-demential Motoric Cognitive Risk Syndrome in Ageing Subjects
|
||
Active, not recruiting |
NCT04240028 -
The Cognitive-Prefrail Syndrome and Its Association With Adverse Health Outcomes
|
||
Completed |
NCT03750682 -
ENGAGE for Brain Health
|
N/A | |
Active, not recruiting |
NCT04275817 -
Cognitive Prefrail and Frailty, and Motoric Cognitive Risk Syndrome: Prevalence and Association With Incident Adverse Health Events
|